Plasma Renin Activity: When to Order This Test

What Plasma Renin Activity Actually Measures

PRA quantifies the enzymatic activity of renin in your blood by measuring the rate at which renin converts angiotensinogen into angiotensin I over a set incubation period. The result is reported in nanograms of angiotensin I generated per milliliter per hour (ng/mL/hr). This differs from a direct renin concentration (DRC) assay, which counts renin molecules rather than their catalytic output. Both tests serve similar clinical purposes, but PRA remains the more widely validated metric in aldosteronism screening studies [1].

The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that starts in the kidneys. Juxtaglomerular cells release renin in response to reduced renal perfusion pressure, sympathetic nervous system activation, or low sodium delivery to the macula densa [2]. Renin then cleaves angiotensinogen (produced by the liver) into angiotensin I, which angiotensin-converting enzyme (ACE) further processes into angiotensin II. Angiotensin II drives aldosterone secretion from the adrenal zona glomerulosa, constricts arterioles, and stimulates sodium reabsorption.

A PRA result is only interpretable alongside a simultaneous serum aldosterone level. The ratio of the two, the ARR, is the metric that flags autonomous aldosterone production. A PRA drawn in isolation tells you whether renin is high, low, or normal, but cannot by itself distinguish between primary and secondary aldosterone excess [3].

When Guidelines Say to Order the Test

The 2016 Endocrine Society Clinical Practice Guideline on primary aldosteronism recommends screening with an ARR in patients who meet any of the following criteria: sustained blood pressure above 150/100 mmHg on three separate measurements, hypertension resistant to three conventional drugs, hypertension with spontaneous or diuretic-induced hypokalemia, hypertension with an adrenal incidentaloma, or hypertension with a family history of early-onset hypertension or stroke before age 40 [3]. The guideline states: "Primary aldosteronism is the most common cause of secondary hypertension, with a prevalence of 5 to 10 percent among hypertensive patients" [3].

Ordering PRA is also appropriate in the pediatric setting when hypertension presents before puberty, or in any adult whose blood pressure spikes before age 30 without an obvious lifestyle explanation [4]. Renal artery stenosis, renin-secreting tumors (extremely rare, with fewer than 100 cases reported in the literature), and some forms of congenital adrenal hyperplasia all produce characteristic PRA patterns that aid differential diagnosis [5].

A practical ordering framework: if the patient has hypertension plus at least one "red flag" (hypokalemia, adrenal mass, family history, age <30, or treatment resistance on three or more drugs), draw a morning paired aldosterone and PRA. Skip the test in straightforward essential hypertension that responds to first-line therapy.

How to Prepare the Patient and Handle the Sample

PRA is notoriously sensitive to preanalytical variables. Poor sample handling is the leading cause of uninterpretable results. The Endocrine Society guideline and most reference laboratories recommend the following protocol [3]:

Correct hypokalemia first. Low potassium independently suppresses aldosterone, which can mask primary aldosteronism and produce a falsely normal ARR. Target a serum potassium of at least 4.0 mEq/L before drawing.

Liberalize sodium intake. Sodium restriction stimulates renin and aldosterone physiologically, confounding the screen. Patients should consume an unrestricted-sodium diet for at least three days before the draw.

Review medications carefully. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) must be stopped for at least four weeks. Beta-blockers, central alpha-agonists, and NSAIDs suppress PRA and should be held for at least two weeks when clinically safe. ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers raise PRA and may cause false-negative ARR results, though the Endocrine Society notes these can be continued if withdrawal is unsafe, provided the clinician interprets results with that context [3].

Draw the sample in the morning (ideally between 8:00 and 10:00 AM) after the patient has been upright and ambulatory for at least two hours. Collect into a pre-chilled EDTA tube, place immediately on ice, and transport to the lab within 30 minutes. Renin degrades at room temperature, and delayed processing falsely lowers PRA [6].

Interpreting Normal, High, and Low PRA Values

A typical reference range for upright PRA in adults is 0.25 to 5.82 ng/mL/hr, though this varies by assay platform and laboratory. The ARR, not the raw PRA value, drives clinical decisions. An ARR above 30 (when aldosterone is measured in ng/dL and PRA in ng/mL/hr) with a plasma aldosterone concentration above 15 ng/dL is considered a positive screen [3].

Low PRA with high aldosterone. This pattern defines primary aldosteronism. The adrenal gland produces aldosterone autonomously, expanding plasma volume and suppressing renin through negative feedback. A 2020 analysis of prospective screening data across 12 centers found that primary aldosteronism accounted for 11.2% of referred hypertensive patients when the ARR screen was applied systematically [7]. Dr. John Funder, who chaired the original Endocrine Society guideline committee, has noted: "The true prevalence of primary aldosteronism has been underestimated for decades because clinicians waited for hypokalemia, which is absent in over half of cases" [3].

High PRA with high aldosterone. Both arms of the axis are activated, pointing toward a secondary cause: renal artery stenosis, renin-secreting tumor, coarctation of the aorta, or chronic diuretic use.

Low PRA with low aldosterone. Consider non-aldosterone mineralocorticoid excess. Causes include Cushing syndrome, apparent mineralocorticoid excess (AME) syndrome, Liddle syndrome, and exogenous mineralocorticoid ingestion (such as licorice abuse containing glycyrrhizin).

High PRA with low or normal aldosterone. This may indicate adrenal insufficiency affecting the zona glomerulosa, advanced renal disease, or angiotensin II receptor subtype abnormalities.

Confirmatory Testing After a Positive ARR Screen

A positive ARR is a screening result, not a diagnosis. The Endocrine Society guideline recommends confirmatory testing with one of four protocols: the oral sodium loading test (3-day high-sodium diet followed by 24-hour urine aldosterone measurement), the intravenous saline infusion test (2 liters of 0.9% NaCl over 4 hours with pre- and post-aldosterone levels), the fludrocortisone suppression test, or the captopril challenge test [3].

In the saline infusion test, post-infusion aldosterone above 10 ng/dL confirms autonomous secretion. Values between 5 and 10 ng/dL are indeterminate. Below 5 ng/dL effectively rules out primary aldosteronism [8].

Following confirmation, adrenal CT is performed to look for a unilateral adenoma. However, CT sensitivity for small aldosterone-producing adenomas (<1 cm) is limited. Adrenal vein sampling (AVS) remains the gold standard for lateralization in patients who are surgical candidates. A 2014 multicenter study (N=291) reported that AVS changed the surgical recommendation in 37.8% of patients compared with CT alone [9].

How PRA Fits Into the Broader Hypertension Workup

PRA testing sits within a structured secondary hypertension evaluation. It is not a stand-alone screening tool for general hypertension. The American Heart Association (AHA) and American College of Cardiology (ACC) 2017 Hypertension Guideline recommend a secondary-cause workup for patients with resistant hypertension, defined as blood pressure remaining above 130/80 mmHg despite three optimally dosed antihypertensives including a diuretic [10].

The workup typically proceeds in parallel: paired aldosterone/PRA for primary aldosteronism, renal artery duplex or CT angiography for renovascular disease, 24-hour urine catecholamines or plasma metanephrines for pheochromocytoma, TSH for thyroid dysfunction, and overnight dexamethasone suppression for Cushing syndrome. PRA values also help classify renovascular hypertension. In atherosclerotic renal artery stenosis, PRA is typically elevated, whereas in fibromuscular dysplasia (more common in women under 50), PRA elevation may be more pronounced and lateralizing [11].

How to Lower or Raise Plasma Renin Activity

PRA is a physiologic marker, not a treatment target. Clinicians do not treat PRA directly. They treat the underlying condition that produces the abnormal value.

To lower elevated PRA: address the stimulus driving renin release. In renovascular hypertension, renal artery revascularization (angioplasty with or without stenting) may normalize renin. In volume-depleted states, restoring intravascular volume through sodium and fluid repletion suppresses renin. Medications that reduce PRA include beta-blockers (which inhibit juxtaglomerular cell renin secretion), NSAIDs (which reduce prostaglandin-mediated renin release), and direct renin inhibitors such as aliskiren [12].

To raise suppressed PRA: in primary aldosteronism caused by a unilateral adenoma, laparoscopic adrenalectomy removes the source of autonomous aldosterone and allows renin to recover. A 2017 retrospective cohort (N=524) found that 37% of patients achieved complete biochemical and clinical cure (defined as normalization of potassium and blood pressure off all medications) after unilateral adrenalectomy [13]. For bilateral adrenal hyperplasia, mineralocorticoid receptor antagonists (spironolactone 25 to 100 mg daily or eplerenone 50 to 200 mg daily) are first-line medical therapy. These agents block aldosterone's effect on the distal nephron and allow partial recovery of PRA through reduced volume expansion [3].

Dietary sodium reduction activates renin physiologically, but this is a normal compensatory response, not a therapeutic goal. Patients on low-sodium diets will show higher PRA values as a reflection of appropriate RAAS activation.

PRA vs. Direct Renin Concentration: Which Test to Order

Some laboratories have transitioned from PRA to direct renin concentration (DRC), which is measured via immunometric assay and reported in mIU/L or pg/mL. DRC is faster to process (no incubation step), less sensitive to temperature during transport, and more easily automated. The 2016 Endocrine Society guideline endorses either PRA or DRC for ARR calculation, though it notes that PRA-based cutoffs are better validated [3].

When using DRC, the ARR threshold changes. A commonly cited cutoff is an aldosterone (ng/dL) to DRC (mIU/L) ratio above 3.7, though laboratories should validate their own thresholds [14]. The AACE 2023 primary aldosteronism consensus statement recommends that clinicians confirm which assay their laboratory uses and apply the corresponding diagnostic cutoff rather than defaulting to PRA-based thresholds [15].

One practical consideration: renin mass (DRC) may be disproportionately elevated relative to enzymatic activity (PRA) in patients taking direct renin inhibitors. If a patient is on aliskiren, PRA is suppressed by the drug's mechanism, while DRC may paradoxically rise due to loss of angiotensin II negative feedback on renin secretion. In these cases, neither assay is interpretable without drug washout [12].

Special Populations and Edge Cases

Pregnancy. PRA rises two- to four-fold by the second trimester due to estrogen-driven hepatic angiotensinogen synthesis. ARR screening during pregnancy is unreliable [16].

Chronic kidney disease (CKD). Patients with eGFR <30 mL/min/1.73 m² often have elevated PRA from reduced renal mass and impaired sodium handling. ARR interpretation requires caution, and consultation with endocrinology is advisable.

Older adults. PRA declines with age. A 1991 population study (N=596) found that mean PRA in normotensive adults over 60 was 40% lower than in adults under 40 [17]. This age-related suppression can mimic the low-PRA pattern of primary aldosteronism, increasing false-positive ARR results in older patients.

Children. Normal PRA ranges are higher in infants and decline through adolescence. Pediatric reference intervals should be used. The Endocrine Society guideline does not provide pediatric-specific ARR cutoffs but recommends subspecialty referral for any child with hypertension and suppressed PRA [3].

Patients with a confirmed diagnosis of primary aldosteronism should undergo screening for target-organ damage, including echocardiography for left ventricular hypertrophy and assessment for microalbuminuria. A 2018 meta-analysis (N=3,838) found that patients with primary aldosteronism had a 2.05-fold higher risk of atrial fibrillation, a 1.77-fold higher risk of heart failure, and a 1.60-fold higher risk of stroke compared with age- and blood-pressure-matched essential hypertension controls [18].